

Basic Pharmacokinetics

SECOND EDITION

Sunil S. Jambhekar BPharm, MS, PhD

Professor and Associate Dean, LECOM-Bradenton, School of Pharmacy, Bradenton, Florida, USA

Philip J. Breen PhD

Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy,
University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA



London • Philadelphia **Pharmaceutical Press**

Contents

Preface	xi
About the authors	xiii
1 Introduction and overview	1
1.1 Use of drugs in disease states	1
1.2 Important definitions and descriptions	2
1.3 Sites of drug administration	4
1.4 Review of ADME processes	5
1.5 Pharmacokinetic models	7
1.6 Rate processes	12
2 Mathematical review	17
2.1 Introduction	17
2.2 A brief history of pharmacokinetics	18
2.3 Hierarchy of algebraic operations	18
2.4 Exponents and logarithms	18
2.5 Variables, constants, and parameters	19
2.6 Significant figures	20
2.7 Units and their manipulation	21
2.8 Slopes, rates, and derivatives	21
2.9 Time expressions	24
2.10 Construction of pharmacokinetic sketches (profiles)	25
3 Intravenous bolus administration (one-compartment model)	29
3.1 Introduction	29
3.2 Useful pharmacokinetic parameters	30
3.3 The apparent volume of distribution (V)	32
3.4 The elimination half life ($t_{1/2}$)	36
3.5 The elimination rate constant (K or K_{el})	38
3.6 Plotting drug concentration versus time	40
3.7 Intravenous bolus administration of drugs: summary	41
3.8 Intravenous bolus administration: monitoring drug in urine	42
3.9 Use of urinary excretion data	43

4	Clearance concepts	55
4.1	Introduction	55
4.2	Clearance definitions	56
4.3	Clearance: rate and concentration	58
4.4	Clearance: tank and faucet analogy	58
4.5	Organ clearance	60
4.6	Physiological approach to clearance	61
4.7	Estimation of systemic clearance	65
4.8	Calculating renal clearance (Cl_r) and metabolic clearance (Cl_m)	66
4.9	Determination of the area under the plasma concentration versus time curve: application of the trapezoidal rule	67
4.10	Elimination mechanism	69
4.11	Use of creatinine clearance to determine renal function	69
	Appendix: Recently developed equations for estimating creatinine clearance and glomerular filtration rate	76
	Problem set 1	79
5	Drug absorption from the gastrointestinal tract	95
5.1	Gastrointestinal tract	95
5.2	Mechanism of drug absorption	98
5.3	Factors affecting passive drug absorption	100
5.4	pH-partition theory of drug absorption	101
6	Extravascular routes of drug administration	105
6.1	Introduction	106
6.2	Drug remaining to be absorbed, or drug remaining at the site of administration	106
6.3	Determination of elimination half life ($t_{1/2}$) and elimination rate constant (K or K_{el})	109
6.4	Absorption rate constant (K_a)	110
6.5	Wagner–Nelson method (one-compartment model) and Loo–Riegelman method (two-compartment model)	111
6.6	Lag time (t_0)	115
6.7	Some important comments on the absorption rate constant	116
6.8	The apparent volume of distribution (V)	116
6.9	Time of maximum drug concentration, peak time (t_{max})	117
6.10	Maximum (peak) plasma concentration (C_p) _{max}	118
6.11	Some general comments	120
6.12	Example for extravascular route of drug administration	121
6.13	Flip-flop kinetics	126
	Problem set 2	127
7	Bioavailability/bioequivalence	137
7.1	Introduction	138
7.2	Important definitions	138
7.3	Types of bioavailability	139

7.4	Bioequivalence	141
7.5	Factors affecting bioavailability	141
7.6	The first-pass effect (presystemic clearance)	142
7.7	Determination of the area under the plasma concentration–time curve and the cumulative amount of drug eliminated in urine	143
7.8	Methods and criteria for bioavailability testing	145
7.9	Characterizing drug absorption from plasma concentration versus time and from urinary data following the administration of a drug via different extravascular routes and/or dosage forms	155
7.10	Equivalency terms	157
7.11	Food and Drug Administration codes	157
7.12	Fallacies on bioequivalence	158
7.13	Evidence of generic bioinequivalence or of therapeutic inequivalence for certain formulations approved by the FDA	159
	Problem set 3	161
8	Factors affecting drug absorption: Physicochemical factors	175
8.1	Dissolution rate	175
8.2	Dissolution process	175
8.3	Noyes–Whitney equation and drug dissolution	176
8.4	Factors affecting the dissolution rate	177
9	Gastrointestinal absorption: Role of the dosage form	187
9.1	Introduction	187
9.2	Solution (elixir, syrup, and solution) as a dosage form	188
9.3	Suspension as a dosage form	188
9.4	Capsule as a dosage form	189
9.5	Tablet as a dosage form	189
9.6	Dissolution methods	191
9.7	Formulation and processing factors	191
9.8	Correlation of <i>in vivo</i> data with <i>in vitro</i> dissolution data	194
10	Continuous intravenous infusion (one-compartment model)	203
10.1	Introduction	203
10.2	Monitoring drug in the body or blood (plasma/serum)	205
10.3	Sampling drug in body or blood during infusion	205
10.4	Sampling blood following cessation of infusion	220
10.5	Use of post-infusion plasma concentration data to obtain half life, elimination rate constant and the apparent volume of distribution	222
10.6	Rowland and Tozer method	225
	Problem set 4	227
11	Multiple dosing: Intravenous bolus administration	237
11.1	Introduction	237
11.2	Useful pharmacokinetic parameters in multiple dosing	241

11.3	Designing or establishing the dosage regimen for a drug	248
11.4	Concept of drug accumulation in the body (R)	249
11.5	Determination of fluctuation (Φ): intravenous bolus administration	251
11.6	Number of doses required to reach a fraction of the steady-state condition	254
11.7	Calculation of loading and maintenance doses	254
11.8	Maximum and minimum drug concentration at steady state	255
12	Multiple dosing: extravascular routes of drug administration	257
12.1	Introduction	257
12.2	The peak time in multiple dosing to steady state (t'_{\max})	259
12.3	Maximum plasma concentration at steady state	260
12.4	Minimum plasma concentration at steady state	261
12.5	“Average” plasma concentration at steady state: extravascular route	262
12.6	Determination of drug accumulation: extravascular route	263
12.7	Calculation of fluctuation factor (Φ) for multiple extravascular dosing	264
12.8	Number of doses required to reach a fraction of steady state: extravascular route	264
12.9	Determination of loading and maintenance dose: extravascular route	265
12.10	Interconversion between loading, maintenance, oral, and intravenous bolus doses	266
	Problem set 5	271
13	Two-compartment model	285
13.1	Introduction	285
13.2	Intravenous bolus administration: two-compartment model	287
13.3	Determination of the post-distribution rate constant (β) and the coefficient B	292
13.4	Determination of the distribution rate constant (α) and the coefficient A	292
13.5	Determination of micro rate constants: the inter-compartmental rate constants (K_{21} and K_{12}) and the pure elimination rate constant (K_{10})	295
13.6	Determination of volumes of distribution (V)	296
13.7	How to obtain the area under the plasma concentration–time curve from time zero to time t and time ∞	298
13.8	General comments	299
13.9	Example	300
13.10	Further calculations to perform and determine the answers	302
13.11	Extravascular dosing of a two-compartment model drug	303
	Problem set 6	305
14	Multiple intermittent infusions	309
14.1	Introduction	309
14.2	Drug concentration guidelines	311
14.3	Example: determination of a multiple intermittent infusion dosing regimen for an aminoglycoside antibiotic	311
14.4	Dose to the patient from a multiple intermittent infusion	313
14.5	Multiple intermittent infusion of a two-compartment drug: vancomycin “peak” at 1 hour post infusion	313

14.6	Vancomycin dosing regimen problem	314
14.7	Adjustment for early or late drug concentrations	315
	Problem set 7	319
15	Nonlinear pharmacokinetics	323
15.1	Introduction	323
15.2	Capacity-limited metabolism	325
15.3	Estimation of Michaelis–Menten parameters (V_{\max} and K_m)	327
15.4	Relationship between the area under the plasma concentration versus time curve and the administered dose	330
15.5	Time to reach a given fraction of steady state	332
15.6	Example: calculation of parameters for phenytoin	333
	Problem set 8	337
16	Drug interactions	341
16.1	Introduction	341
16.2	The effect of protein-binding interactions	342
16.3	The effect of tissue-binding interactions	348
16.4	Cytochrome P450-based drug interactions	349
16.5	Drug interactions linked to transporters	355
	Problem set 9	357
17	Pharmacokinetic and pharmacodynamic relationships	359
17.1	Introduction	359
17.2	Generation of a pharmacokinetic– pharmacodynamic (PKPD) equation	361
17.3	Pharmacokinetic and pharmacodynamic drug interactions	364
	Problem set 10	367
18	Metabolite pharmacokinetics	369
18.1	Introduction	369
18.2	General model	370
18.3	Single intravenous bolus of drug conforming to a one-compartment model	370
18.4	Single oral dose of drug conforming to a one-compartment model	382
18.5	Intravenous infusion of a one-compartment model parent drug	384
18.6	Chronic dosing to steady state	385
18.7	Study design required to obtain various metabolite pharmacokinetic parameters	388
18.8	Computer-aided simulation and fitting of metabolite pharmacokinetic data	388
18.9	Case in point: meperidine and normeperidine	388
18.10	Active metabolites in renal dysfunction	388
18.11	Sample metabolite pharmacokinetics calculations	393
19	Pharmacokinetic data fitting	395
19.1	Introduction	395
19.2	Pharmacokinetic parameter determination	395

19.3	Nonlinear regression	397
19.4	Goodness of fit indices	398
19.5	Ways to improve fit	401
19.6	Evaluation of program output	401
19.7	How are the values of the parameters determined?	404
19.8	Problems that may occur during a nonlinear regression run	407
19.9	Weighting of data points	408
19.10	Simulation	409
19.11	Initial estimates	411
19.12	Conclusion	412
20	Pharmacokinetics and pharmacodynamics of biotechnology drugs	413
20.1	Introduction	413
20.2	Proteins and peptides	413
20.3	Monoclonal antibodies	419
20.4	Oligonucleotides	423
20.5	Vaccines (immunotherapy)	424
20.6	Gene therapies	425
	Appendix: Statistical moment theory in pharmacokinetics	427
A.1	Introduction	427
A.2	Statistical moment theory	428
A.3	Applications	439
	Glossary	443
	References	453
	Index	461